Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

1.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

Gynecol Oncol. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. Epub 2013 May 27.

PMID:
23721800
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA.

Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23.

PMID:
21862685
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ.

Cancer Res. 2011 Jun 1;71(11):3991-4001. doi: 10.1158/0008-5472.CAN-10-3175. Epub 2011 Apr 15.

PMID:
21498635
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.

PMID:
19816957
[PubMed - indexed for MEDLINE]
Free Article
5.

Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.

Jiang Y, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL, Jin XM.

Gastric Cancer. 2012 Oct;15(4):440-50. doi: 10.1007/s10120-012-0140-y. Epub 2012 Feb 14.

PMID:
22395309
[PubMed - indexed for MEDLINE]
6.

Metformin targets ovarian cancer stem cells in vitro and in vivo.

Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK, Buckanovich RJ.

Gynecol Oncol. 2012 Nov;127(2):390-7. doi: 10.1016/j.ygyno.2012.07.115. Epub 2012 Aug 2.

PMID:
22864111
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.

Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W.

Int J Cancer. 2012 Jan 1;130(1):29-39. doi: 10.1002/ijc.25967. Epub 2011 Apr 8.

PMID:
21480217
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Targeted inhibition of CD133+ cells in oral cancer cell lines.

Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, O'Malley BW Jr, Akintoye SO, DiRienzo JM.

J Dent Res. 2011 May;90(5):638-45. doi: 10.1177/0022034510393511. Epub 2011 Jan 10.

PMID:
21220361
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.

Gallmeier E, Hermann PC, Mueller MT, Machado JG, Ziesch A, De Toni EN, Palagyi A, Eisen C, Ellwart JW, Rivera J, Rubio-Viqueira B, Hidalgo M, Bunz F, Göke B, Heeschen C.

Stem Cells. 2011 Mar;29(3):418-29. doi: 10.1002/stem.595.

PMID:
21308861
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.

Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, Chang YL, Hsu HS, Lan YT, Chen KH, Chi CW, Chiou SH, Yang DM, Lee CH.

J Pharmacol Exp Ther. 2012 May;341(2):410-23. doi: 10.1124/jpet.111.188730. Epub 2012 Feb 10.

PMID:
22328572
[PubMed - indexed for MEDLINE]
Free Article
11.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

PMID:
19805294
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties.

Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A.

Cell Transplant. 2010;19(6):865-77. doi: 10.3727/096368910X508997. Epub 2010 Jun 29.

PMID:
20587145
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29.

PMID:
19451087
[PubMed - indexed for MEDLINE]
Free Article
14.

CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.

PMID:
23197865
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Radiother Oncol. 2009 Sep;92(3):353-61. doi: 10.1016/j.radonc.2009.06.034. Epub 2009 Aug 21.

PMID:
19699546
[PubMed - indexed for MEDLINE]
16.

The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.

Bidlingmaier S, Zhu X, Liu B.

J Mol Med (Berl). 2008 Sep;86(9):1025-32. doi: 10.1007/s00109-008-0357-8. Epub 2008 Jun 6. Review.

PMID:
18535813
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.

Gambelli F, Sasdelli F, Manini I, Gambarana C, Oliveri G, Miracco C, Sorrentino V.

Cell Biol Int. 2012 Jan;36(1):29-38. doi: 10.1042/CBI20110013.

PMID:
21916848
[PubMed - indexed for MEDLINE]
18.

In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.

Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J.

Head Neck. 2009 Jan;31(1):94-101. doi: 10.1002/hed.20935.

PMID:
18853445
[PubMed - indexed for MEDLINE]
19.

Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.

Guo R, Wu Q, Liu F, Wang Y.

Oncol Rep. 2011 Jan;25(1):141-6.

PMID:
21109969
[PubMed - indexed for MEDLINE]
20.

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.

PMID:
20935265
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk